Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer-1

Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with Thoracic Radiation Therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable Non-Small-Cell Lung Cancer (NSCLC)

Gulmez, İNCİ
GULEC, Mustafa
CANOZ, O
BILGIN, Mehmet
OZKAN, M
ER, O
KARAHACIOGLU, Eray
EROGLU, Celalettin
ALTYNBAS, M
Kaplan, Bünyamin

December 2004

Concurrent chemoradiotherapy plays an important role in the treatment of unresectable NSCLC. This ph...

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Langer, Corey J.
O’Byrne, Kenneth J.
Socinski, Mark A.
Mikhailov, Sergei M.
Leśniewski-Kmak, Krzysztof
Smakal, Martin
Ciuleanu, Tudor E.
Orlov, Sergey V.
Dediu, Mircea
Heigener, David
Eisenfeld, Amy J.
Sandalic, Larissa
Oldham, Fred B.
Singer, Jack W.
Ross, Helen J.

June 2008

IntroductionPerformance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience mo...

V. Hess
M. W. Verrill
C. C. Bomphray
M. M. Vaughan
M. Allen
M. E. Gore

January 2002

carboplatin–paclitaxel causes toxicity. Toxicity can be reduced by weekly administration. We examine...

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer-0

Perran F Yumuk (71049)
Nazim S Turhal (71050)
Mahmut Gumus (71051)
Nilgun F Hatabay (71052)
Orhan Turken (71053)
Alper Ozkan (71054)
Taflan Salepci (71055)
Mehmet Aliustaoglu (71056)
Rengin Ahiskali (71057)

December 2011

Copyright information:Taken from "Results of paclitaxel (day 1 and 8) and carboplat...

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

Ozkan, A
Salepci, T
ALİUSTAOĞLU, MEHMET
Ahiskali, R
Turken, O
Hatabay, NF
Gumus, M
Turhal, NS
Yumuk, PF

January 2005

Background: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lu...

Results of published studies on the combination of carboplatin and paclitaxel in patients with metastatic melanoma.

Annette Pflugfelder (355962)
Thomas K. Eigentler (191111)
Ulrike Keim (355963)
Benjamin Weide (191119)
Ulrike Leiter (191103)
Kristian Ikenberg (157286)
Mark Berneburg (181828)
Claus Garbe (48881)

February 2013

Results of published studies on the combination of carboplatin and paclitaxel in patients with me...

The combination of carboplatin and weekly paclitaxel: A safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study

A. Fabi
M. Barduagni
V. Ferraresi
Enrico Cortesi
T. Gamucci
F. De Marinis
R. Saltarelli
A. Gabriele
M. Pellicciotta
A. Ceribelli
S. De Marco
F. Facciolo
F. Cognetti

January 2004

The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

Langer, C. J.
O'Byrne, Kenneth J.
Socinski, M. A.
Mikhailov, S. M.
Leśniewski-Kmak, K.
Smakal, M.
Ciuleanu, T. E.
Orlov, S. V.
Dediu, M.
Heigener, D.
Eisenfeld, A. J.
Sandalic, L.
Oldham, F. B.
Singer, J. W.
Ross, H. J.

January 2008

Free to read at publisher's site.\ud \ud INTRODUCTION: \ud Performance status (PS) 2 patients with n...

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer

Langer, Corey
O'Byrne, Kenneth
Socinski, Mark
Mikhailov, Sergei
Lesniewski-Kmak, Krzysztof
Smakal, Martin
Ciuleanu, Tudor
Orlov, Sergey
Dediu, Mircea
Heigener, David
Eisenfeld, Amy
Sandalic, Larissa
Oldham, Fred
Singer, Jack
Ross, Helen

January 2008

Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small ce...

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer-1

Matthew A Beldner (86640)
Carol A Sherman (86641)
Mark R Green (86642)
Elizabeth Garrett-Mayer (86643)
Uzair Chaudhary (86644)
Mario L Meyer (86645)
Andrew S Kraft (86646)
Alberto J Montero (86647)

December 2011

Copyright information:Taken from "Phase I dose escalation study of vinorelbine and ...

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer-0

Matthew A Beldner (86640)
Carol A Sherman (86641)
Mark R Green (86642)
Elizabeth Garrett-Mayer (86643)
Uzair Chaudhary (86644)
Mario L Meyer (86645)
Andrew S Kraft (86646)
Alberto J Montero (86647)

December 2011

Copyright information:Taken from "Phase I dose escalation study of vinorelbine and ...

Combination of paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)

Ho, JCM
Ip, S
Ip, MSM
Wang, J
Lam, WK
Yan, C
Lam, CL
Lam, FM
Tsang, KWT

January 2000

Session - Respiratory & Critical Care Medicine: no. G-RC-13published_or_final_versio

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Socinski, Mark A.
Manikhas, Georgiy M.
Stroyakovsky, Daniil L.
Makhson, Anatoly N.
Cheporov, Sergey V.
Orlov, Sergei V.
Yablonsky, Petr K.
Bhar, Paul H.
Iglesias, Jose

June 2010

IntroductionThis nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and we...

Phase I Trial of Carboplatin and Weekly Paclitaxel in Patients With Advanced Non-small-cell Lung Cancer

Junko Kikuchi
Koichi Yamazaki
Ichiro Kinoshita
Hajime Asahina
Mikado Imura
Eiki Kikuchi
Jun Konishi
Naofumi Shinagawa
Hiromitsu Oki
Hirotoshi Dosaka-akita
Masaharu Nishimura

January 2004

Objective: This study was designed to determine the maximum tolerated dose of paclitaxel administere...

Lung Cancer Highlights

Thomas J. Lynch
Early Stage
Non-small Cell
Lung Cancer

January 1999

Adjuvant therapy does not work. Second-line therapy works modestly. Paclitaxel/carboplatin and cispl...

Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with Thoracic Radiation Therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable Non-Small-Cell Lung Cancer (NSCLC)

Gulmez, İNCİ
GULEC, Mustafa
CANOZ, O
BILGIN, Mehmet
OZKAN, M
ER, O
KARAHACIOGLU, Eray
EROGLU, Celalettin
ALTYNBAS, M
Kaplan, Bünyamin

December 2004

Concurrent chemoradiotherapy plays an important role in the treatment of unresectable NSCLC. This ph...

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Langer, Corey J.
O’Byrne, Kenneth J.
Socinski, Mark A.
Mikhailov, Sergei M.
Leśniewski-Kmak, Krzysztof
Smakal, Martin
Ciuleanu, Tudor E.
Orlov, Sergey V.
Dediu, Mircea
Heigener, David
Eisenfeld, Amy J.
Sandalic, Larissa
Oldham, Fred B.
Singer, Jack W.
Ross, Helen J.

June 2008

IntroductionPerformance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience mo...

V. Hess
M. W. Verrill
C. C. Bomphray
M. M. Vaughan
M. Allen
M. E. Gore

January 2002

carboplatin–paclitaxel causes toxicity. Toxicity can be reduced by weekly administration. We examine...

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer-0

Perran F Yumuk (71049)
Nazim S Turhal (71050)
Mahmut Gumus (71051)
Nilgun F Hatabay (71052)
Orhan Turken (71053)
Alper Ozkan (71054)
Taflan Salepci (71055)
Mehmet Aliustaoglu (71056)
Rengin Ahiskali (71057)

December 2011

Copyright information:Taken from "Results of paclitaxel (day 1 and 8) and carboplat...

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer

Ozkan, A
Salepci, T
ALİUSTAOĞLU, MEHMET
Ahiskali, R
Turken, O
Hatabay, NF
Gumus, M
Turhal, NS
Yumuk, PF

January 2005

Background: Both paclitaxel ( P) and carboplatin ( C) have significant activity in non-small cell lu...

Results of published studies on the combination of carboplatin and paclitaxel in patients with metastatic melanoma.

Annette Pflugfelder (355962)
Thomas K. Eigentler (191111)
Ulrike Keim (355963)
Benjamin Weide (191119)
Ulrike Leiter (191103)
Kristian Ikenberg (157286)
Mark Berneburg (181828)
Claus Garbe (48881)

February 2013

Results of published studies on the combination of carboplatin and paclitaxel in patients with me...

The combination of carboplatin and weekly paclitaxel: A safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study

A. Fabi
M. Barduagni
V. Ferraresi
Enrico Cortesi
T. Gamucci
F. De Marinis
R. Saltarelli
A. Gabriele
M. Pellicciotta
A. Ceribelli
S. De Marco
F. Facciolo
F. Cognetti

January 2004

The combination of carboplatin and paclitaxel given every three weeks is a tolerated and reasonably ...

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

Langer, C. J.
O'Byrne, Kenneth J.
Socinski, M. A.
Mikhailov, S. M.
Leśniewski-Kmak, K.
Smakal, M.
Ciuleanu, T. E.
Orlov, S. V.
Dediu, M.
Heigener, D.
Eisenfeld, A. J.
Sandalic, L.
Oldham, F. B.
Singer, J. W.
Ross, H. J.

January 2008

Free to read at publisher's site.\ud \ud INTRODUCTION: \ud Performance status (PS) 2 patients with n...

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer

Langer, Corey
O'Byrne, Kenneth
Socinski, Mark
Mikhailov, Sergei
Lesniewski-Kmak, Krzysztof
Smakal, Martin
Ciuleanu, Tudor
Orlov, Sergey
Dediu, Mircea
Heigener, David
Eisenfeld, Amy
Sandalic, Larissa
Oldham, Fred
Singer, Jack
Ross, Helen

January 2008

Free to read at publisher's site. INTRODUCTION: Performance status (PS) 2 patients with non-small ce...

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer-1

Matthew A Beldner (86640)
Carol A Sherman (86641)
Mark R Green (86642)
Elizabeth Garrett-Mayer (86643)
Uzair Chaudhary (86644)
Mario L Meyer (86645)
Andrew S Kraft (86646)
Alberto J Montero (86647)

December 2011

Copyright information:Taken from "Phase I dose escalation study of vinorelbine and ...

Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer-0

Matthew A Beldner (86640)
Carol A Sherman (86641)
Mark R Green (86642)
Elizabeth Garrett-Mayer (86643)
Uzair Chaudhary (86644)
Mario L Meyer (86645)
Andrew S Kraft (86646)
Alberto J Montero (86647)

December 2011

Copyright information:Taken from "Phase I dose escalation study of vinorelbine and ...

Combination of paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)

Ho, JCM
Ip, S
Ip, MSM
Wang, J
Lam, WK
Yan, C
Lam, CL
Lam, FM
Tsang, KWT

January 2000

Session - Respiratory & Critical Care Medicine: no. G-RC-13published_or_final_versio

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Socinski, Mark A.
Manikhas, Georgiy M.
Stroyakovsky, Daniil L.
Makhson, Anatoly N.
Cheporov, Sergey V.
Orlov, Sergei V.
Yablonsky, Petr K.
Bhar, Paul H.
Iglesias, Jose

June 2010

IntroductionThis nonrandomized study aimed to identify the optimal dose of every-3-week (q3w) and we...

Phase I Trial of Carboplatin and Weekly Paclitaxel in Patients With Advanced Non-small-cell Lung Cancer

Junko Kikuchi
Koichi Yamazaki
Ichiro Kinoshita
Hajime Asahina
Mikado Imura
Eiki Kikuchi
Jun Konishi
Naofumi Shinagawa
Hiromitsu Oki
Hirotoshi Dosaka-akita
Masaharu Nishimura

January 2004

Objective: This study was designed to determine the maximum tolerated dose of paclitaxel administere...

Lung Cancer Highlights

Thomas J. Lynch
Early Stage
Non-small Cell
Lung Cancer

January 1999

Adjuvant therapy does not work. Second-line therapy works modestly. Paclitaxel/carboplatin and cispl...

Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with Thoracic Radiation Therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable Non-Small-Cell Lung Cancer (NSCLC)

Gulmez, İNCİ
GULEC, Mustafa
CANOZ, O
BILGIN, Mehmet
OZKAN, M
ER, O
KARAHACIOGLU, Eray
EROGLU, Celalettin
ALTYNBAS, M
Kaplan, Bünyamin

December 2004

Concurrent chemoradiotherapy plays an important role in the treatment of unresectable NSCLC. This ph...

Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer

Langer, Corey J.
O’Byrne, Kenneth J.
Socinski, Mark A.
Mikhailov, Sergei M.
Leśniewski-Kmak, Krzysztof
Smakal, Martin
Ciuleanu, Tudor E.
Orlov, Sergey V.
Dediu, Mircea
Heigener, David
Eisenfeld, Amy J.
Sandalic, Larissa
Oldham, Fred B.
Singer, Jack W.
Ross, Helen J.

June 2008

IntroductionPerformance status (PS) 2 patients with non-small cell lung cancer (NSCLC) experience mo...

V. Hess
M. W. Verrill
C. C. Bomphray
M. M. Vaughan
M. Allen
M. E. Gore

January 2002

carboplatin–paclitaxel causes toxicity. Toxicity can be reduced by weekly administration. We examine...

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer-1

Abstract

Extracted data

Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer-1

Abstract

Extracted data

Related items

Related items